In this webinar, Prof. David Selwood, Professor of Biological and Medical Chemistry, Wolfson Institute for Biomedical Research, UCL, explores the subject of GCI/Biacore System and and interact with research fellows. This is part of the UCL's Research Capabilities Webinar Series 2025. This webinar series is organised by the UCL Therapeutic Innovation Networks (TINs) - Small Molecules to highlight UCL’s Research Capabilities that enable effective translational research for patient and public benefit. The series aims to encourage multidisciplinary collaborations within and beyond UCL. Academics from the UCL biomedical community are invited to share subjects of interest from their research expertise and interact with research fellows.

5

6/4/2025

UCL, together with its partner hospitals, has successfully established itself as a leading global centre for developing and trialling next-generation advanced medical therapies, according to a report from the UCL Translational Research Office and UCL Business Ltd. In this video, Dr Jane Kinghorn, Director of the UCL Translational Research Office, discusses what sets UCL apart from other academic institutions and how UCL supports researchers in bringing ATMPs to patients. Dr Anne Lane, CEO of UCL Business, explains how UCL Business supports the commercialisation of ATMPs and addresses the associated challenges.

33

6/3/2025

Preclinical research struggles with limitations that hinder progress. In this webinar, Professor Kalaskar, from the Department of Ortho and MSK Science, will explain how bioprinting technology could address these challenges and offer a game-changing solution. He will present how bioprinting can revolutionise the field by showcasing specific innovations developed by his team. The seminar will conclude with insights on the evolving regulatory landscape, including a discussion on the FDA Modernization Act 2 and its potential impact on future pre-clinical and clinical research.

24

7/17/2024

Phage display is a recombinant screening technology that involves the construction of bacteriophage libraries that express large numbers (1*10^11) of peptides or proteins as fusions to the major or minor coat proteins of bacteriophage species such as M13. Phage display is routinely used in the pharmaceutical industry to develop fully human antibodies against a range of different diseases targets, including cancer and inflammatory diseases. Dr Chris Morris, from the School of Pharmacy, presented examples of how phage display can be applied to the identification of peptide-based motifs for targeting biological structures at three different length scales – whole cells in melanoma skin cancer, individual glycan-binding proteins in human lung infections and subcellular, non-canonical DNA structures.

30

6/6/2024

Electron microscopy (EM) provides ultrastructural information at nanometre resolution which, when combined with a wide variety of sample preparation techniques and multimodal approaches, can be an exceptionally powerful research tool. With continual advances being made, and for example volume EM being named by Nature as “One of the seven technologies to watch in 2023”, Jemima Burden, Head of Electron Microscopy at the Laboratory for Molecular Cell Biology, will share some of the approaches available to address research questions related to basic cell and developmental biology, through to virology, immunology, neurodegenerative diseases, regeneration, cancer biology and drug and therapeutic development. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit.

11

4/15/2024

Antisense oligonucleotides (AONs) can be used to alter many aspects of gene expression, from splice isoform switching to reducing, or increasing, gene expression. The retina is an accessible part of the nervous system and is an ideal paradigm to study how AONs can be used to combat neurodegeneration. During this webinar, Prof. Mike Cheetham from the Institute of Ophthalmology will give an overview of AON design and show how they can be used as therapies for inherited retinal dystrophies (IRDs), from stem cell derived models of disease, to in vivo and clinical trials. This will exemplify the potential of AONs to treat genetic disease, and IRDs in particular. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encourage multidisciplinary collaborations across departments. Academics from the UCL biome

25

3/27/2024

This special two-part seminar delves into innovative approaches to treatment, highlighting the value of in vitro models in advancing healthcare. Part 1: Dr Lucy Granat from the Alzheimer's Research UK UCL Drug Discovery Institute will discuss their use of in vitro models in understanding neurodegenerative diseases. This includes validating new drug targets and developing new treatments, ultimately aiming to accelerate progress in tackling these challenging conditions. Part 2: Dr Mattia Gerli, from the Division of Surgery and Interventional Science, will present recent research on generating primary organoid models using amniotic and tracheal fluids. This holds immense potential for personalised regenerative medicine tailored to the foetus. This is part of the webinar series by the UCL Therapeutic Innovation Networks (TINs) to highlight UCL’s Research Infrastructure and Capabilities that enable effective translation of products toward patient/public benefit. The series aims to encoura

19

3/21/2024

(Note: the webinar finishes at timecode 50:00) In this webinar, Dr Darren Nesbeth, a synthetic biologist at the UCL Biochemical Engineering Department, explored the daunting technical challenges faced by the nascent cultivated meat industry and also the opportunities for researchers in regenerative medicine, and other fields, to come together and develop the innovations that will pave the way to a more sustainable food future.

81

2/23/2024